Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $27.4 million versus the consensus estimate of $28.91 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.